Home ETF List About

ETF Holdings Breakdown of SNDX

Stock NameSyndax Pharmaceuticals Inc
TickerSNDX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS87164F1057
LEI529900OF94TRHKZVBS87

SNDX institutional holdings

The following institutional investment holdings of SNDX have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 57,081USD 958,390 -5.6% 16.79  
2025-11-12 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 11,677 -0.3%USD 196,057 -5.9% 16.79  
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 55,463 0.3%USD 931,224 -5.3% 16.79  
2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 55,463 0.3%USD 931,224 -5.3% 16.79  
2025-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 572USD 9,604 -5.6% 16.79  
Total =180,256 USD 3,026,499
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SNDX

Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Stifel Nicolaus
Stifel Nicolaus began coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report released on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $44.00 price target on the stock. Several other brokerages have also issued reports on SNDX. BTIG Research raised their target price on Syndax Pharmaceuticals from […] - 2025-09-11 04:40:27
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $36.91
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been given a consensus rating of “Buy” by the twelve research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the […] - 2025-08-13 03:14:52
Traders Purchase Large Volume of Call Options on Syndax Pharmaceuticals (NASDAQ:SNDX)
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors acquired 13,389 call options on the company. Thisrepresentsanincreaseof904% compared to the typical daily volume of 1,333 call options. Analysts Set New Price Targets A number of research analysts recently weighed in on SNDX shares. Citigroup […] - 2025-08-13 02:14:52
Zurcher Kantonalbank Zurich Cantonalbank Sells 4,731 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Zurcher Kantonalbank Zurich Cantonalbank cut its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 26.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,260 shares of the company’s stock after selling 4,731 shares during the quarter. Zurcher Kantonalbank Zurich […] - 2025-08-11 05:21:01
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up After Better-Than-Expected Earnings
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) gapped up prior to trading on Tuesday following a stronger than expected earnings report. The stock had previously closed at $10.38, but opened at $12.41. Syndax Pharmaceuticals shares last traded at $12.02, with a volume of 1,551,513 shares traded. The company reported ($0.83) earnings per share (EPS) […] - 2025-08-07 02:13:02
UBS Group Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $35.00
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price objective trimmed by UBS Group from $37.00 to $35.00 in a report published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock. Several other research firms also recently weighed in on SNDX. Scotiabank upped their price objective on shares of Syndax […] - 2025-07-18 05:05:16
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% After Analyst Downgrade
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) dropped 6% during mid-day trading on Tuesday after UBS Group lowered their price target on the stock from $37.00 to $35.00. UBS Group currently has a buy rating on the stock. Syndax Pharmaceuticals traded as low as $9.30 and last traded at $9.26. Approximately 282,152 shares were […] - 2025-07-16 02:46:49
Wealth Enhancement Advisory Services LLC Invests $162,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Wealth Enhancement Advisory Services LLC acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,172 shares of the company’s stock, valued at approximately $162,000. A number of other institutional investors and hedge […] - 2025-07-10 04:20:57
KBC Group NV Sells 1,774 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
KBC Group NV decreased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 25.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 5,180 shares of the company’s stock after selling 1,774 shares during the quarter. KBC Group NV’s holdings in Syndax Pharmaceuticals were worth $64,000 as of its […] - 2025-07-09 04:33:51
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.91 Average PT from Analysts
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 year price […] - 2025-06-24 02:36:53
ProShare Advisors LLC Has $359,000 Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
ProShare Advisors LLC grew its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 32.2% during the fourth quarter, Holdings Channel reports. The firm owned 27,183 shares of the company’s stock after acquiring an additional 6,627 shares during the quarter. ProShare Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $359,000 at the end of […] - 2025-05-29 05:04:57
Millennium Management LLC Sells 533,153 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Millennium Management LLC trimmed its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 47.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 586,810 shares of the company’s stock after selling 533,153 shares during the quarter. Millennium Management LLC’s holdings in Syndax Pharmaceuticals were worth $7,758,000 at the end of the most recent […] - 2025-05-27 04:54:51
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. […] - 2025-05-27 02:49:01
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC reduced its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 89.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 20,657 shares of the company’s stock after selling 166,806 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $273,000 as of its most recent […] - 2025-05-13 06:15:02
Dimensional Fund Advisors LP Has $4.38 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Dimensional Fund Advisors LP increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 594.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 331,300 shares of the company’s stock after buying an additional 283,577 shares during the […] - 2025-05-13 04:38:47
Marshall Wace LLP Decreases Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Marshall Wace LLP lessened its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 98.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,624 shares of the company’s stock after selling 977,280 shares during the period. Marshall Wace LLP’s holdings in Syndax […] - 2025-05-06 04:44:58
Tower Research Capital LLC TRC Has $240,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Tower Research Capital LLC TRC boosted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 179.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,190 shares of the company’s stock after purchasing an additional 11,681 shares during the period. Tower […] - 2025-05-05 05:30:49
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Consensus Price Target from Brokerages
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price […] - 2025-05-05 02:49:06
Geode Capital Management LLC Sells 3,966 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Geode Capital Management LLC trimmed its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 0.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,973,116 shares of the company’s stock after selling 3,966 shares during the period. […] - 2025-04-18 04:34:51
KLP Kapitalforvaltning AS Invests $219,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
KLP Kapitalforvaltning AS acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 16,600 shares of the company’s stock, valued at approximately $219,000. Other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new […] - 2025-04-08 05:04:47
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Acquired by Teacher Retirement System of Texas
Teacher Retirement System of Texas lifted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 18.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,769 shares of the company’s stock after purchasing an additional 3,585 shares during the period. Teacher Retirement System of Texas’ holdings in Syndax Pharmaceuticals were worth $301,000 […] - 2025-04-02 04:42:46
Signaturefd LLC Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Signaturefd LLC lessened its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 45.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,078 shares of the company’s stock after selling 1,745 shares during the quarter. Signaturefd LLC’s holdings in Syndax Pharmaceuticals were worth $27,000 as of […] - 2025-03-26 05:48:52
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.5% on Analyst Upgrade
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) shares shot up 5.5% on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $39.00 to $41.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Syndax Pharmaceuticals traded as high as $13.51 and last traded at $13.84. 164,424 […] - 2025-03-21 03:42:50
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.4% on Disappointing Earnings
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) were down 7.4% during trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $14.23 and last traded at $14.34. Approximately 1,069,083 shares were traded during trading, a decline of 53% from the average daily volume of 2,257,449 shares. […] - 2025-03-06 06:13:39
Citigroup Lowers Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $42.00
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target reduced by Citigroup from $45.00 to $42.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock. Other research analysts also recently issued reports about the company. The Goldman Sachs Group lifted their target price […] - 2025-03-05 06:45:05
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Sanctuary Advisors LLC
Sanctuary Advisors LLC lowered its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 18.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 25,178 shares of the company’s stock after selling 5,750 shares during the quarter. Sanctuary Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $358,000 at the end of the most […] - 2025-03-04 06:20:47
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.20
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among […] - 2025-02-19 04:30:59
1,940 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by R Squared Ltd
R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 1,940 shares of the company’s stock, valued at approximately $26,000. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. […] - 2025-02-05 06:42:48

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.